AI assistant
Nuvation Bio Inc. — Director's Dealing 2021
Feb 12, 2021
32154_dirs_2021-02-12_3414f7b2-b6bd-4245-a151-32365140822c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2021-02-10
Reporting Person: Bazemore Robert B (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-10 | Stock Option (Right to Buy) | $4.60 | A | 51703 | Acquired | 2030-10-04 | Class A Common Stock (51703) | Direct |
| 2021-02-10 | Stock Option (Right to Buy) | $1.74 | A | 187658 | Acquired | 2030-07-21 | Class A Common Stock (187658) | Direct |
Footnotes
F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer").
F2: Options vest in 48 equal monthly installments from October 5, 2020.
F3: Received in exchange for an option to purchase 51,630 shares of Legacy Nuvation Class A Common Stock.
F4: Options vest in 48 equal monthly installments from July 22, 2020.
F5: Received in exchange for an option to purchase 187,392 shares of Legacy Nuvation Class A Common Stock.